IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive ...
A study presented at the Society of Interventional Radiology’s 37th Annual Scientific Meeting in San Francisco, Calif. shows that percutaneous cryoablation may be provide another treatment alternative ...
"ProSense® received a high level of interest at this prestigious breast cancer conference in Europe where our cryoablation system is gaining increasing commercial traction driven by regulatory ...
CAESAREA, Israel, Oct. 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
March 11, 2009 (San Diego, California) — Interventional cryoablation is an effective treatment for small renal tumors, and should be the gold standard or first treatment option for all patients with ...
Percutaneous radiofrequency ablation, although a promising therapy for small, solid renal tumors, is less suitable for large tumors or masses adjacent to critical structures, such as the bowel, and ...
Feasibility study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II-IIIA non-small cell lung cancer. Background: Percutaneous cryoablation for lung tumors ...
Nephron-sparing surgery for small-to-medium sized renal tumors has undoubtedly become a standard of patient management in the 21 st century. The recent trends toward nephron sparing stem from an ...
Racial and gender disparities in renal cell carcinoma. The effects of HDIL-2 in combination with pazopanib or sunitinib on PBMCs’ function and RCC cells’ apoptosis: Preliminary in vitro data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results